Article
CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy.
International journal of cancer - 16 May 1995
Yacyshyn M B, Poppema S, Berg A, MacLean G D, Reddish M A, Meikle A, Longenecker B M
Abstract excerpt
Lymphocyte activation markers CD69 and HLA-DR were studied in metastatic breast and ovarian cancer patients who received active specific immunotherapy (ASI) using cancer vaccines containing the synthetic tumor-associated antigen sialyl-Tn or the Thomsen-Friedenreich antigen conjugated to KLH plus DETOX adjuvant. Breast cancer patients who showed prolonged survival following ASI had lower numbers of total CD69+...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.